Shares of Solid Biosciences ( SLDB) - Get Report dropped Tuesday after the developer of a Duchenne muscular-dystrophy treatment reported that a patient had an adverse event in an trial of its gene-therapy candidate. The Cambridge, Mass., company said that six patients in its ongoing clinical study showed promising results. A seventh patient "was safely dosed, with transient and manageable adverse events, none of which were serious," it said in a statement "The totality of data collected, and the reinitiation of dosing, support the continued enrollment of patients into the Ignite DMD study," the company said. "We are encouraged with the successful resumption of dosing in the Ignite DMD trial under our amended clinical protocol and using SGT-001 manufactured with a second-generation process," Barry Byrne, a physician who is principal investigator of the study, said.